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The most common mutation in human melanoma, BRAF(V600E), activates the serine/threonine kinase BRAF and causes excessive activity in the mitogen-activated protein kinase pathway 1, 2 . BRAF(V600E) mutations are also present in benign melanocytic naevi 3 , highlighting the importance of additional genetic alterations in the genesis of malignant tumours. Such changes include recurrent copy number variations that result in the amplification of oncogenes 4, 5 . For certain amplifications, the large number of genes in the interval has precluded an understanding of the cooperating oncogenic events. Here we have used a zebrafish melanoma model to test genes in a recurrently amplified region of chromosome 1 for the ability to cooperate with BRAF(V600E) and accelerate melanoma. SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was found to accelerate melanoma formation significantly in zebrafish. Chromatin immunoprecipitation coupled with massively parallel DNA sequencing and gene expression analyses uncovered genes, including HOX genes, that are transcriptionally dysregulated in response to increased levels of SETDB1. Our studies establish SETDB1 as an oncogene in melanoma and underscore the role of chromatin factors in regulating tumorigenesis.
To identify genes that promote melanoma, we focused on genomic regions that are subject to copy number amplification in human tumour samples. In a study of 101 cell lines and short-term cultures of melanoma cells, chromosome 1q21 (chr1: 147.2-149.2 megabases) was identified as a recurrently amplified interval 6 (Fig. 1a) . The same region was implicated in another comprehensive analysis of copy number variation in melanoma 4 . To test candidate genes from this interval for the ability to accelerate melanoma, we developed an assay in transgenic (Tg) zebrafish in which BRAF(V600E) is expressed under the control of a melanocytespecific gene (mitfa) promoter on a p53 (also known as tp53) mutant background (p53 2/2 ) ( Supplementary Fig. 1 ). Melanomas and melanocytes that develop in Tg(mitfa:BRAF(V600E)); p53 2/2 zebrafish 7 are suppressed by a mitfa 2/2 mutation. We engineered a transposonbased vector called miniCoopR that rescues melanocytes and melanomas in a Tg(mitfa:BRAF(V600E)); p53 2/2 ; mitfa 2/2 strain and drives the expression of a candidate gene in these rescued tissues. We identified genes that were present in the human 1q21 region and were overexpressed as messenger RNAs in 1q21-amplified melanomas based on Affymetrix microarrays. Candidate human genes were cloned into the miniCoopR vector and injected into one-cell stage Tg(mitfa:BRAF(V600E)); p53 significance of copy number amplification along chromosome 1 in human melanoma samples, as assessed by using the algorithm GISTIC (genomic identification of significant targets in cancer) 8, 20 . Significance values were determined by the false discovery rate (FDR) test. Right, copy number profiles in the human 1q21 interval in melanoma samples (vertical bars). The positions of SETDB1 (dashed line) and MCL1 (arrowhead) are indicated. Mb, megabase. b, The Tg(mitfa:BRAF(V600E)); p53 2/2 ; mitfa 2/2 strain (top) was injected with miniCoopR-cloned candidate oncogenes. In animals injected with miniCoopR-SETDB1 (bottom), the melanocytes are rescued, and melanomas (arrow) rapidly develop. c, Melanoma-free survival curves for Tg(mitfa:BRAF(V600E)); p53 2/2 ; mitfa 2/2 zebrafish injected with miniCoopR-SETDB1 (weighted average of 2 independent experiments, n 5 70) or miniCoopR-EGFP (weighted average of 3 independent experiments, n 5 125).
incidence curves for the resultant adults showed that one gene in this interval, SETDB1, significantly accelerated melanoma onset (P 5 9.4 3 10
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, logrank chi-squared test; Fig. 1b , c and Supplementary Fig. 2) .
As in melanoma, SETDB1 is focally amplified in non-small-cell lung cancer, small-cell lung cancer, ovarian cancer, hepatocellular carcinoma and breast cancer ( Supplementary Fig. 3 ). The anti-apoptotic gene MCL1 resides near SETDB1 in the 1q21 interval, and knockdown of MCL1 has been shown to diminish non-small-cell lung cancer proliferation and xenograft outgrowth 8 . However, MCL1 is not overexpressed in the 1q21-amplified melanoma samples, so it was not tested in this study. No other gene accelerated the onset of melanomas, suggesting that SETDB1 is a crucial gene that is amplified in the chromosome 1q21 interval. Using fluorescence in situ hybridization, we observed SETDB1 amplification in short-term cultures of human melanoma cells ( Supplementary Fig. 4) , directly confirming the array-based copy number data from which our study originated.
Melanomas overexpressing SETDB1 were more aggressive than tumours overexpressing enhanced green fluorescent protein (EGFP) when analysed at an equivalent stage and in the same Tg(mitfa:BRAF(V600E)); p53 
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, Fisher's exact test)). MiniCoopR-SETDB1 transgenic melanomas had more extensive nuclear pleomorphism and larger nuclei than control tumours ( Supplementary  Fig. 5 ). By contrast, miniCoopR-SETDB1 tumours showed similar levels of BRAF protein to control tumours, indicating that SETDB1 did not accelerate melanoma formation by altering expression of the BRAF(V600E) transgene (Supplementary Fig. 6 ).
Melanocytes overexpressing SETDB1 grew in confluent patches in zebrafish, unlike melanocytes in the EGFP-overexpressing control zebrafish, which grew in a wild-type stripe pattern. We analysed the genetic interactions that are responsible for these pigmentation differences. SETDB1-expressing melanocytes in the Tg(mitfa:BRAF(V600E)); mitfa 2/2 strain formed confluent patches, but SETDB1-expressing melanocytes in the p53 2/2 ; mitfa 2/2 strain grew in a striped pattern (Fig. 2b) . Although SETDB1 and BRAF(V600E) cooperated to override normal pigment patterning, no tumours arose in miniCoopR-SETDB1-injected Tg(mitfa:BRAF(V600E)); mitfa 2/2 zebrafish, indicating that SETDB1 overexpression does not have the same effect as loss of p53 in tumour formation.
BRAF(V600E) induces senescence in human naevi and in cultured mammalian melanocytes 9 , and we suspected that the pigmentation differences might result from a failure of senescence and excess melanocyte proliferation caused by SETDB1. Using senescenceassociated b-Galactosidase (SA-b-Gal) staining 10, 11 , we confirmed that BRAF(V600E) induces senescence in zebrafish melanocytes in vivo ( Supplementary Fig. 7a-c) . We stained miniCoopR-rescued melanocytes and found SETDB1-expressing melanocytes to be less senescent than those expressing only EGFP (Fig. 2c) . SETDB1-expressing melanocytes also lacked the flattened morphology of senescent cells (Supplementary Fig. 7d ). These results suggest that SETDB1 overexpression may contribute to melanoma formation by abrogating oncogeneinduced senescence.
To understand the gene expression changes that occur when SETDB1 is overexpressed, we performed microarray analyses of zebrafish melanomas. We defined a gene signature comprising 67 human orthologues of genes that are downregulated in SETDB1-overexpressing zebrafish melanomas ( Fig. 3a ) and tested the relationship between this signature and SETDB1 expression in human melanomas. Using gene set enrichment analysis (GSEA) 12, 13 , we found that the gene signature was inversely correlated with SETDB1 expression across a panel of 93 cell lines and short-term cultures of melanoma cells (Fig. 3b) . SETDB1 overexpression led to a broad pattern of transcriptional changes, including conserved downregulation of a group of genes that is enriched for HOX genes and for transcriptional regulators.
To identify the direct targets of SETDB1 across the genome in melanoma cells, we performed chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq). We identified SETDB1 targets from WM262, a short-term culture of melanoma cells with high levels of SETDB1 expression, and from WM451Lu, a short-term a, Transverse sections of zebrafish melanomas at 2 weeks post onset of melanoma, visualized by staining with haematoxylin and eosin. At this time point, dorsal miniCoopR-EGFP melanomas (left) have exophytic growth, whereas miniCoopR-SETDB1 melanomas (right) have invaded from the skin, through the collagen-rich stratum compactum (sc) of the dermis, into the underlying musculature. Scale bar, 70 mm. b, SETDB1 interacts with BRAF(V600E), affecting the pigmentation pattern, but the p53 2/2 mutation is required for melanoma formation. miniCoopR-EGFP or miniCoopR-SETDB1 was injected into the indicated transgenic strains. The photographs indicate pigmentation pattern differences before the time point at which melanomas begin to form in the Tg(mitfa:BRAF(V600E)); p53
; mitfa 2/2 background. Percentages indicate the melanoma incidence at 12 weeks of age; n 5 number of fish. c, SETDB1 abrogates BRAF(V600E)-induced senescence. Left, brightfield pseudocoloured photomicrographs of SA-b-Gal staining performed on scaleassociated melanocytes. Centre and right, fluorescent photomicrographs of the same melanocytes. In this experiment, miniCoopR-rescued melanocytes express mitfa-promoter-driven EGFP (centre) and MITFA (right). Multiple nuclei (arrowheads) are present in BRAF(V600E)-expressing melanocytes. The percentage of senescent melanocytes is indicated (P 5 7.3 3 10
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, chi-squared test); n 5 number of cells. Scale bar, 10 mm.
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culture of melanoma cells with low levels of SETDB1 ( Supplementary  Fig. 8 ). These short-term cultures harbour the BRAF(V600E) mutation ( Supplementary Fig. 9 ), and their proliferation is sensitive to changes in SETDB1 levels ( Supplementary Figs 10 and 11) . In murine embryonic stem cells, SETDB1 binds to the promoters of genes encoding developmental regulators, including Hox genes 14 . We observed differential binding of SETDB1 to genes in the HOXA cluster in melanoma cell lines with high and low levels of SETDB1 expression; SETDB1 is bound to HOXA genes in WM262 cells, whereas there is minimal binding in WM451Lu cells (Fig. 3c and Supplementary Tables 1 and  2 ). SETDB1 catalyses the trimethylation of histone H3 lysine 9 (H3K9me3), thereby promoting repression of its target genes. ChIPseq for the H3K9me3 mark showed that H3K9me3 is present at the HOXA locus in WM262 cells but absent in WM451Lu cells (Fig. 3c) . HOX gene expression is inversely correlated with SETDB1 levels in short-term cultures of melanoma cells (Fig. 3b) , suggesting that enhanced target gene binding and repression may have a role in the SETDB1-mediated acceleration of melanoma onset. Additional ChIPseq, for MCAF1 (also known as AM and ATF7IP; a methyltransferasestimulatory cofactor of SETDB1) 15 in WM262 cells, suggests that the effects of SETDB1 overexpression are mediated in part by MCAF1 ( Supplementary Fig. 12 ). We assayed the effects of SETDB1 overexpression on target genes by infecting WM451Lu cells with a SETDB1-expressing lentivirus. Using SETDB1 ChIP-seq data from WM451Lu cells, we found that SETDB1-bound targets are significantly enriched in downregulated genes but not upregulated ones ( Supplementary Fig. 13 and Supplementary Table 3 ), suggesting that a major consequence of SETDB1 amplification is repression of SETDB1-bound target genes. However, many SETDB1 target genes in both WM451Lu and WM262 short-term cultures of melanoma cells are not methylated, and additional analyses show a relationship between increasing SETDB1 levels and increasing expression of many SETDB1 target genes ( Supplementary Fig. 14) .
To obtain a mechanistic insight into the role of SETDB1 in regulating gene expression, we undertook genetic and biochemical studies that evaluate methyltransferase activity. Recently, a complex containing SETDB1 and the H3K9 methyltransferases SUV39H1, G9A (also known as EHMT2) and GLP (also known as EHMT1) was discovered 16 .
To examine the possibility that other methyltransferases act together with SETDB1 to modulate melanoma onset, we tested whether EGFP   SETDB1   tbcb  ftr11  ahr1b  LOC567869  irgf1  LOC1001147851  LOC797620  zbtb12.1  LOC794624  zgc:103657  nsd1b  LOC567384  capn5a  ehd2  prep  LOC562176  drd2a  LOC100151078  spon2  LOC100334603  ankrd24  LOC565006  pskh1  LOC558990  LOC565819  arhgef17  si:dkey-83f6.3  LOC793395  cttnbp2nl  LOC100334631  LOC563403  pcdh10b  LOC562935  LOC559089  met  tmtc2  ptprk  zgc:113105  hoxb6a  LOC569146  LOC798799  wu:fc23b07  zgc:63990  dlx2a  ntrk3b  kcnc4  LOC561756  hoxb2a  chrnb2  hsp47  pdgfrb2  acvrl1  atr  hoxb5a  wu:fc18f06  hoxa3a  sema3c  cacna1d  hoxb7a  f10  cdh10  hoxb4a  hoxa4a  dkk1a  hoxb3a ; mitfa 2/2 zebrafish expressing SUV39H1 (P 5 6.74 3 10 28 versus miniCoopR-EGFP, logrank chi-squared test) or expressing the methyltransferase-deficient SETDB1 variants SETDB1(H1224K) (P 5 0.24 versus miniCoopR-SETDB1, and P 5 8.4 3 10 25 versus miniCoopR-EGFP) or SETDB1(C1226A) (P 5 0.20 versus miniCoopR-SETDB1, and P 5 1.3 3 10 211 versus miniCoopR-EGFP). e, In vitro reconstitution of methyltransferase complexes containing SETDB1 and SUV39H1 variants. The sequential purification of glutathione S-transferase (GST)-tagged SUV39H1, Flag-tagged GLP and haemagglutinin (HA)-tagged G9A proteins was followed by western blotting using antibodies specific for the proteins and protein tags indicated on the left. Sequential purifications indicate that mutant SETDB1 proteins copurify in a methyltransferase complex, as does wild-type (WT) SETDB1. f, Histone methylation assays of complexes purified from C2C12 myoblast cells. Complexes containing WT or mutant SETDB1 can catalyse the transfer of radiolabelled methyl groups to histone H3, as detected by fluorography.
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SUV39H1 could accelerate melanoma formation in zebrafish. As was the case for SETDB1, overexpression of SUV39H1 led to the formation of confluent melanocyte patches, and it accelerated melanoma onset (Fig. 3d) . We next examined the consequences of mutations that render SETDB1 enzymatically inactive. Enzymatically deficient SETDB1 was capable of incorporating into the methyltransferase complex in vitro (Fig. 3e) and in vivo (Supplementary Fig. 15 ). Furthermore, in the context of enzymatically deficient SETDB1, the complex retained methyltransferase activity (Fig. 3f and Supplementary Fig. 16 ) and binding site localization (Supplementary Fig. 17 ). Last, the melanoma incidence curves for two methyltransferase-deficient SETDB1 mutants were similar to each other and to the melanoma incidence curve for zebrafish that overexpress wild-type SETDB1 (Fig. 3d) . Our studies suggest a model in which activity of the methyltransferase complex containing SETDB1 and SUV39H1 alters gene expression in a way that leads to the acceleration of melanoma onset and to increased invasiveness.
To determine the extent of SETDB1 overexpression in human melanomas, and to examine potential clinical implications, we performed immunohistochemistry on melanoma tissue microarrays. After confirming antibody specificity ( Supplementary Fig. 18 ), we observed high levels of SETDB1 expression in 5% of normal melanocytes (n 5 20), 15% of benign naevi (n 5 20) and 70% of malignant melanomas (n 5 91) (Fig. 4) . On the basis of our observations of premalignant melanocytic lesions in zebrafish, we speculate that human naevi that overexpress SETDB1 are more likely to undergo oncogenic progression than naevi with basal levels of SETDB1 expression. These data indicate that the majority of malignant human melanomas overexpress the SETDB1 protein.
In this study, we adapted the zebrafish as a platform for cancer gene discovery. Through the creation and analysis of more than 3,000 transgenic animals, SETDB1 was identified as a gene capable of accelerating melanoma formation in cooperation with BRAF(V600E). Amplification of the 1q21 chromosomal interval in melanoma does not preferentially occur together with the BRAF(V600E) mutation (P 5 0.28, two-sample t-test). Therefore, it is probable that the tumour-promoting activity of SETDB1 does not exclusively depend on BRAF(V600E), which is common in melanomas but is found less frequently in other tumour types that have 1q21 amplification. SETDB1 forms a multimeric complex with SUV39H1 and other H3K9 methyltransferases. On the basis of our findings, we speculate that SETDB1 overexpression can increase the activity of the H3K9 methyltransferase complex, leading to alterations in its target specificity. Inactivating mutations in histone methyltransferases and histone demethylases were recently described in renal cell carcinoma 17, 18 . Our study lends functional support to the idea that perturbation of histone methylation promotes cancer. Moreover, SETDB1 is focally amplified in a broad range of malignancies, suggesting that alterations in histone methyltransferase activity could define a biologically related subset of cancers.
METHODS SUMMARY
miniCoopR assay. The miniCoopR vector was constructed by inserting a zebrafish mitfa minigene (consisting of promoter, open reading frame and 39-untranslated region) into the BglII restriction site of the plasmid pDestTol2pA2 (ref. 19 ). Individual miniCoopR clones were created by MultiSite Gateway recombination (Invitrogen) using human full-length open reading frames. Twenty-five picograms of each miniCoopR-candidate clone and 25 pg mRNA encoding the Tol2 transposase were microinjected into one-cell zebrafish embryos generated from an incross of Tg(mitfa:BRAF(V600E)); p53
; mitfa 2/2 zebrafish. Rescued animals were scored weekly for the presence of visible tumours. Senescence assay. SA-b-Gal staining was performed as described previously 10 , except that scales plucked from the dorsum of melanocyte-rescued zebrafish were stained instead of tissue sections. This assay was performed on an albino(b4) mutant background so that melanin pigment would not obscure SA-b-Gal staining. Experimental animals were injected with 20 pg miniCoopR-SETDB1 plus 10 pg miniCoopR-EGFP, and control animals were injected with 30 pg miniCoopR-EGFP. Rescued melanocytes were recognized as EGFP-positive cells. Gene expression. From zebrafish, total RNA was extracted from four miniCoopR-SETDB1 melanomas and four miniCoopR-EGFP melanomas. Total RNA from each was used for the synthesis of cDNA, which was hybridized to a 385K microarray (NimbleGen 071105_Zv7_EXPR). Zebrafish genes that were downregulated by SETDB1 were selected by a fold change of .5 (when comparing the level of expression in miniCoopR-EGFP melanomas and the level in miniCoopR-SETDB1 melanomas) and then filtered by a 'SETDB1 specificity score', which was defined as a fold change of .3 when comparing the level of expression in Tg(mitfa:BRAF(V600E)); p53 2/2 melanomas with that of miniCoopR-SETDB1 melanomas. Immunohistochemistry. Human melanoma tissue microarrays were independently analysed for SETDB1 protein by immunohistochemistry, using a rabbit polyclonal antibody (Sigma HPA018142, at a 1/200 dilution) and a mouse monoclonal antibody (4A3, Sigma WH0009869M7, 1/400 dilution), with a purple substrate for the secondary antibody (VIP substrate, Vector Labs). A methyl green counterstain was used. zebrafish. Transgenic animals were selected based on the presence of rescued melanocytes at 48 h post fertilization. Rescued animals were scored weekly for the presence of visible tumours. Tumour invasion assay. Zebrafish with dorsal melanomas between the head and dorsal fin were isolated, and tumours were allowed to progress for 2 weeks, at which time the animals were killed. Tumours were formalin fixed, embedded and sectioned transversely to assess invasion. Senescence assay. SA-b-Gal staining was performed as described previously 10 , except that scales plucked from the dorsum of melanocyte-rescued zebrafish were stained instead of tissue sections. This assay was performed on an albino(b4) mutant background so that melanin pigment would not obscure SA-b-Gal staining. Experimental animals were injected with 20 pg miniCoopR-SETDB1 plus 10 pg miniCoopR-EGFP, and control animals were injected with 30 pg miniCoopR-EGFP. Rescued melanocytes were recognized as EGFP-positive cells. Gene expression and GSEA. From zebrafish, total RNA was extracted from four miniCoopR-SETDB1 melanomas and four miniCoopR-EGFP melanomas. Total RNA from each was used for the synthesis of cDNA, which was hybridized to a 385K microarray (NimbleGen 071105_Zv7_EXPR). Zebrafish genes that were downregulated by SETDB1 were selected by a fold change of .5 (when comparing the level of expression in miniCoopR-EGFP melanomas and the level in miniCoopR-SETDB1 melanomas) and then filtered by a 'SETDB1 specificity score', which was defined as a fold change of .3 when comparing the level of expression in Tg(mitfa:BRAF(V600E)); p53 2/2 melanomas with that of miniCoopR-SETDB1 melanomas. Human orthologues of SETDB1-downregulated genes were identified for GSEA (http://www.broadinstitute.org/gsea/). For GSEA of SETDB1-downregulated and SETDB1 'bound-bound' genes, a rank-ordered gene list was derived from the expression profiles of 93 melanoma cell lines and short-term cultures of melanoma cells 6 , using SETDB1 expression level as a continuous variable. In WM451Lu cells, the dose of SETDB1 lentiviral infection was titrated to achieve SETDB1 expression levels comparable to those in short-term cultures of melanoma cells with high levels of SETDB1 expression. Total RNA was extracted and then amplified and hybridized to a Human Gene 1.0 ST Array (Affymetrix). Control gene expression values were obtained from WM451Lu cells infected with EGFPexpressing lentivirus. ChIP. ChIP was performed from short-term cultures of WM262 and WM451Lu cells, and ChIP-seq data were analysed as described previously 14 . Methyltransferase complex reconstitution. In vitro-translated Flag-GLP, HA-G9A and untagged SETDB1 (wild type (WT) or the indicated mutant) were incubated for 4 h at 4 uC with 5 mg GST, GST-SUV39H1(WT) or GST-SUV39H1(H324K) mutant immobilized on agarose-glutathione beads. Beads were then extensively washed, as described previously 16 , and protein complexes were eluted with free glutathione. The eluate was then subjected to an overnight Flag immunoprecipitation at 4 uC using Flag-agarose. After extensive washing, protein complexes were eluted with 0.1 M glycine, pH 3.0. The glycine was then neutralized with NaOH, and the eluate was renatured for 1 h at room temperature then incubated overnight at 4 uC with HA-resin. The HA-resin was then washed, and the protein complexes were eluted with SDS. Ten per cent of the input and 100% of the HA eluate were resolved by SDS-PAGE and were analysed by western blotting with the indicated antibodies. The top of the membrane was revealed with three different antibodies (anti-SETDB1, anti-HA and anti-Flag antibody) using two stripping steps. Histone methylation assay. Purified complexes were incubated with 5 mg core histones (Upstate 13-107) and 1.5 mCi S-adenosyl-L-[methyl-
